Ceramide Transfer Protein (CERTL)
- Product Code: X2379P
- Size: 100 µg
- Availability:
In Stock - Price (USD): $355
Cat #
Data Sheet
Product Name
Ceramide Transfer Protein (CERTL)
Synonyms
Lipid-transfer protein CERT, Goodpasture antigen-binding protein isoform 2, GPBP26, GPBP, Collagen type IV alpha-3-binding protein, StAR-related lipid transfer protein 11, StARD11, START domain-containing protein 11, COL4A3BP, STARD11
Host/Source
Rabbit
Isotype
IgG
Product Type
Antigen Immunoaffinity Purified Polyclonal
Reactivity
Human
Applications
Western Blot
Purification
Antigen Immunoaffiinity Purification
Size
100 µg
Price (USD)
$355
Background
CERT mediates the ATP-dependent ER-to-Golgi transfer of ceramide in a non-vesicular manner. The biosynthesis of lipids involves steps that occur in different intracellular compartments. The movement of lipids within these compartments is important in lipid-mediated signalling. Human CERT is identical to a splice variant of human Goodpasture antigen-binding protein (GPBP26).
CERT contains a phosphoinositide-binding pleckstrin-homology (PH) domain (which targets CERT to the Golgi by binding phosphatidylinositol-4-phosphate (PtdIns4P)), a middle region, and a putative lipid-transfer-catalysing domain called START. CERT and CERTL can specifically extract ceramide from phospholipid bilayers in a START-domain-dependent manner. CERT interacts with ER membranes and specifically extracts ceramide. CERT catalyses both the specific extraction of ceramide from donor vesicles and its transfer to acceptor vesicles. CERT can associate with the Golgi in a PtdIns4P dependent manner.
Immunogen
Synthetic peptide derived from human CERTL protein
Positive Control
Ovary, human liver
Formulation
Provided as solution in phosphate buffered saline with 0.08% sodium azide
Customer Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles
Target Molecular Weight
70835
Product Image
Image Legend
Immunohistochemical staining of normal human liver tissue using CERT antibody (Cat. No. X2379P) at 15 µg/ml
Database Links:
| SwissProt | Q9Y5P4 | Human |
References
1. Hanada K., Kumagai K., Yasuda S., Miura Y., Kawano M., Fukasawa M., Nishijima M.;Molecular machinery for non-vesicular trafficking of ceramide.; Nature 426:803-809(2003).
2. Raya A., Revert F., Navarro S., Saus J.; Characterization of a novel type of serine/threonine kinase that specifically phosphorylates the human goodpasture antigen.; J. Biol. Chem. 274:12642-12649(1999).
3. Raya A., Revert-Ros F., Martinez-Martinez P., Navarro S., Rosello E., Vieites B., Granero F., Forteza J., Saus J.; Goodpasture antigen-binding protein, the kinase that phosphorylates the Goodpasture antigen, is an alternatively spliced variant implicated in autoimmune pathogenesis.; J. Biol. Chem. 275:40392-40399(2000).
4. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).; Genome Res. 14:2121-2127(2004).
5. Ogi T., Yamamoto Y., Ohmori H.; Homo sapiens genomic sequence, containing DINB1 and GPBP gene.; Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
6. Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.; Global, in vivo, and site-specific phosphorylation dynamics in signaling networks.; Cell 127:635-648(2006).
